Compare COCH & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | COCH | BOLD |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.9M | 54.5M |
| IPO Year | 2021 | 2024 |
| Metric | COCH | BOLD |
|---|---|---|
| Price | $6.26 | $2.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $21.67 | N/A |
| AVG Volume (30 Days) | 12.7K | ★ 163.8K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.45 | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $241,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.11 | N/A |
| 52 Week Low | $5.36 | $0.96 |
| 52 Week High | $66.06 | $3.16 |
| Indicator | COCH | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 43.14 | 44.24 |
| Support Level | $5.36 | $2.37 |
| Resistance Level | $40.14 | $2.71 |
| Average True Range (ATR) | 1.89 | 0.15 |
| MACD | -0.42 | 0.02 |
| Stochastic Oscillator | 2.08 | 39.02 |
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.